MESA LABORATORIES INC /CO/ (MLAB)
Sector: Industrial Instruments For Measurement, Display, and Control
Industry: Medical - Specialties
Mesa Laboratories, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 119.47 | 128.60 | 119.47 | 128.25 | 109,672 |
| Nov 5, 2026 | 124.86 | 124.86 | 118.01 | 119.30 | 107,612 |
| Nov 4, 2026 | 128.10 | 131.71 | 126.03 | 126.19 | 110,563 |
| Nov 3, 2026 | 123.82 | 127.44 | 123.74 | 125.48 | 91,471 |
| Nov 2, 2026 | 129.74 | 129.80 | 121.26 | 121.97 | 153,255 |
| Oct 30, 2026 | 132.35 | 132.55 | 127.08 | 127.81 | 73,172 |
| Oct 29, 2026 | 132.98 | 134.38 | 131.65 | 133.03 | 60,916 |
| Oct 28, 2026 | 128.35 | 133.78 | 128.35 | 131.32 | 143,437 |
| Oct 27, 2026 | 130.86 | 133.41 | 128.66 | 129.25 | 90,091 |
| Oct 26, 2026 | 128.87 | 131.19 | 128.87 | 129.87 | 52,472 |
| Oct 23, 2026 | 127.90 | 129.63 | 124.95 | 128.66 | 88,260 |
| Oct 22, 2026 | 129.27 | 131.01 | 127.59 | 129.10 | 77,461 |
| Oct 21, 2026 | 124.21 | 129.78 | 123.76 | 129.20 | 84,176 |
| Oct 20, 2026 | 123.25 | 128.27 | 122.52 | 125.16 | 77,219 |
| Oct 19, 2026 | 123.79 | 125.49 | 122.96 | 123.31 | 75,323 |
| Oct 16, 2026 | 127.96 | 128.14 | 122.23 | 122.48 | 74,353 |
| Oct 15, 2026 | 125.18 | 129.06 | 125.00 | 127.74 | 100,252 |
| Oct 14, 2026 | 125.19 | 129.38 | 125.19 | 126.16 | 79,581 |
| Oct 13, 2026 | 127.76 | 129.69 | 126.80 | 127.56 | 108,693 |
| Oct 12, 2026 | 127.36 | 128.53 | 126.10 | 128.07 | 105,000 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Withholding/Transfer | 1.2K | -- | Oct 13, 2026 | |
| Director | Grant/Award | 1.8K | -- | Sep 9, 2026 | |
| Director | Grant/Award | 2.5K | -- | Sep 9, 2026 | |
| Director | Grant/Award | 1.8K | -- | Sep 9, 2026 | |
| Director | Grant/Award | 1.8K | -- | Sep 9, 2026 | |
| Director | Grant/Award | 2.4K | -- | Sep 9, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Conestoga Capital Advisors · filed Jan 2025 | 618.1K | 11.0% | 13G |
Long Path Partners LP | 477.1K | 8.5% | 13F |
Long Path Smaller Companies Fund, LP · also on 13F· joint filing· may incl. warrants· filed Jul 2026 | 477.1K | 8.5% | 13G |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Oct 2026 | 443.7K | 7.9% | 13G |
BlackRock, Inc. | 440.6K | 7.9% | 13F |
Wasatch Advisors LP · also on 13F· may incl. warrants· filed Oct 2026 | 387.1K | 6.9% | 13G |
WASATCH ADVISORS LP | 387.1K | 6.9% | 13F |
ROYCE & ASSOCIATES LP · also on 13F· may incl. warrants· filed Apr 2025 | 271.1K | 4.8% | 13G |
Boston Partners | 265.1K | 4.7% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 237.5K | 4.2% | 13F |
Insiders
- Sullivan John JamesDirector
- Hall ShannonDirector
- Ladiwala Shiraz ShabanaliDirector
- Tripeny R TonyDirector
- Capone Mark ChristopherDirector
- Alltoft Jennifer SadieDirector
- Kadia SiddharthaPresident and CEO
- Sakys JohnCFO
- Archbold Brian DavidSVP Operations
- Crennen Lyndsey ElizabethCAO
Mesa Laboratories, Inc. (MLAB) operates as a global enterprise focused on the creation, production, and distribution of essential life science tools, quality assurance products, and specialized services.
Its market reach extends across the United States, Europe, the Asia Pacific region, and other international territories.
The company's operations are organized into four distinct segments: 1. Sterilization and Disinfection Control: This division manufactures and supplies biological, chemical, and cleaning indicators designed to verify the effectiveness of sterilization and disinfection protocols. These products are vital for industries such as hospitals, dental practices, medical device manufacturing, and pharmaceuticals.
Additionally, it offers specialized testing and laboratory services, primarily catering to the dental sector. 2. Biopharmaceutical Development: This segment is dedicated to developing, producing, and marketing automated solutions for protein analysis, including immunoassays, and comprehensive peptide synthesis technologies.
Its portfolio encompasses analysis equipment, CDs, kits, and buffers for protein analysis, alongside peptide synthesizers that automate the chemical creation of peptides. These synthesized peptides are utilized in the development of therapeutic agents, biomaterials, cosmetic products, and general scientific research. 3. Calibration Solutions: This division designs, manufactures, and commercializes quality control and calibration instruments. These products are crucial for accurately measuring and calibrating parameters such as temperature, pressure, pH, and humidity, ensuring health and safety standards. Their applications span hospitals, medical device and pharmaceutical manufacturing facilities, and various laboratory and healthcare environments. Key offerings include continuous monitoring systems, dialysate meters and their consumables, data logging devices, gas flow calibration and air sampling equipment, and torque testing systems. 4. Clinical Genomics: This segment innovates, produces, and provides advanced genetic analysis tools. A prominent offering is the MassARRAY system, complemented by essential consumables like chips, panels, and chemical reagent solutions. These tools enable clinical laboratories to perform genomic testing across several therapeutic areas, including newborn screening, pharmacogenomics, and oncology. Mesa Laboratories, Inc. was established in 1982 and is headquartered in Lakewood, Colorado.
based on 5.60M shares outstanding
30d Avg
93.15K
60d Avg
107.27K
90d Avg
124.57K